DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0063810 A1 Vergez Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0063810 A1 Vergez Et Al US 2006OO63810A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0063810 A1 Vergez et al. (43) Pub. Date: Mar. 23, 2006 (54) COMBINATION TREATMENT FOR Publication Classification IMPARED MOTOR FUNCTION IN PARKINSON'S DISEASE (51) Int. Cl. A61K 31/452 (2006.01) (76) Inventors: Juan A. Vergez, Buenos Aires (AR); A61K 31/343 (2006.01) Alan B. Lanier, Raleigh, NC (US); A61K 3III.37 (2006.01) Ethel C. Feleder, Buenos Aires (AR); (52) U.S. Cl. ........................... 514/321; 514/469; 514/649 Glenn A. Meyer, Wilmington, NC (US); Marcelo A. Ricci, Buenos Aires (AR); Joaquina Faour, Buenos Aires (57) ABSTRACT (AR) The invention provides a method, and dosage form therefor, Correspondence Address: of treating impaired motor function associated with Parkin INNOVAR, LLC Son's disease, anti-Parkinson's drug treatment, e.g. L-Dopa PO BOX 250647 therapy, and/or dementia associated with Parkinson's dis ease. The invention includes the combined administration of PLANO, TX 75025 (US) an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or Venlafax (21) Appl. No.: 11/215,797 ine, or an NMDA receptor antagonist and an anxiolytic (22) Filed: Aug. 30, 2005 agent, e.g., amantadine and buspirone or traZOdone, for the amelioration of undesired tremors, akinesia, dyskinesia, or Related U.S. Application Data bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage (63) Continuation-in-part of application No. PCT/CR04/ form. One embodiment includes a combination dosage form 00003, filed on Mar. 5, 2004. containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing (60) Provisional application No. 60/452,077, filed on Mar. a controlled release of an NMDA receptor antagonist and a 5, 2003. Provisional application No. 60/452,055, filed rapid release of a neuroactive agent after administration to a on Mar. 5, 2003. Subject. Patent Application Publication Mar. 23, 2006 Sheet 1 of 4 US 2006/0063810 A1 FIG. 1 Approximate Amantadine Release O 5 10 15 20 25 30 Time (h) Patent Application Publication Mar. 23, 2006 Sheet 2 of 4 US 2006/0063810 A1 FIG. 2 UPDRS II: PATIENTS 1-4 and A-D 90 1 2 3 4 5 6 7 Visit No. -0-UPDRS IIl Subject 1 -- UPDRS IIl Subject 2 UPDRS III Subject 3 -la. UPDRS Il Subject 4 --UPDRS IIl Subject A -o-UPDRS IIl Subject B --UPDRS Il Subject C -UPDRS IIl Subject D Patent Application Publication Mar. 23, 2006 Sheet 3 of 4 US 2006/0063810 A1 FIG. 3 UPDRS IV: SUBJECTS 1-4 and A-D 1 2 3 4 5 & 7 Visit No. --UPDRS IV Subject 1 -0-UPDRSM Subject 2 UPDRS IV Subject 3 .x. UPDRSM Subject 4 -k-UPDRS IV Subject A -o-UPDRSM Subject B -- UPDRS IV Subject C -UPDRS IV Subject D Patent Application Publication Mar. 23, 2006 Sheet 4 of 4 US 2006/0063810 A1 FIG. 4 influence of Amantadine-Citalopram as Add-on Therapy (N=28 Patients +/- Std. Error) i 1 4 10 Weeks of Therapy US 2006/OO6381.0 A1 Mar. 23, 2006 COMBINATION TREATMENT FOR IMPARED SSRI antidepressants concomitant with anti-Parkinson drug MOTOR FUNCTION IN PARKINSON'S DISEASE therapy actually worSens motor impairment. 0006 Korsgaard et al. (Clin. Neuropharmacol., (1986), CROSS-REFERENCE TO EARLIER FILED 9(1), 52-7) report that citalopram has no significant effect in APPLICATIONS treating tardive dyskinesia or Parkinsonism. 0001. The present application is a continuation-in-part of 0007 Rampello et al. (Clin. Neuropharmacol., (January and claims the benefit of priority of PCT International Patent February 2002), 25(1), 21-24) report that when combined Application No. PCT/CR04/00003 filed Mar. 5, 2004, which with levodopa, citalopram induces an improvement of motor claims the benefit of priority of U.S. Provisional Application performance, in particular of Subscores 23 and 31 of Unified for Patent No. 60/452,077 filed Mar. 5, 2003, the entire Parkinson's Disease Rating Scale both in depressed and in disclosures of which are hereby incorporated by reference. nondepressed patients with Parkinson's disease. FIELD OF THE INVENTION 0008 Osmotic devices and other sustained/extended release devices containing citalopram are known in the art. 0002 This invention pertains to a method, and dosage Such devices have been disclosed by, for example, Kuhrts, form therefore, of treating impaired motor function associ in U.S. Patent Application Publication No. 2002/0098239, ated with Parkinson's disease, anti-Parkinson's drug treat which discloses a Sustained release device and Suggests ment, and/or dementia associated with Parkinson's disease. citalopram as a drug Suitable for use in the device. Masters, More particularly, it pertains to the combined oral admin in U.S. Patent Application Publication No. 2002/0106410, istration of an NMDA receptor antagonist and a neuroactive discloses a controlled release device, and Suggests citalo agent for the treatment of impaired motor function. pram as a drug Suitable for use in the device. Elema et al., in U.S. Patent Application Publication No. 2002/0160050, BACKGROUND OF THE INVENTION disclose a melt granulated modified release dosage form and 0.003 Antidepressants are widely known for use in treat claim citalopram as a drug used in the device. Chopra et al., ing depression in different disease States. Antidepressant use in U.S. Patent Application Publication No. 2003/0003151, in the treatment of depression associated with Parkinson's disclose a controlled release dosage form having a com disease, Alzheimer's disease and various types of dementia pressed core and claim citalopram as a drug used in the is well known. Many patients have reportedly been admin device. istered an antidepressant while also receiving anti-Parkin 0009 BIOVAIL(R) is reportedly currently developing a Sons, anti-Alzheimer's or anti-dementia drug therapy. Vari controlled release dosage form containing citalopram for the ous Scientific publications and patents Specifically mention treatment of depression; however, this product does not the use of citalopram in treating depression associated with include amantadine. these disorders. However, citalopram is not generally known for its use in the treatment of tremors associated with these 0010 Buspirone, a 5-HT1A agonist, is a recognized disorders. anxiolytic agent. BuSpirone is primarily active in dopamin ergic pathways. It has the properties of both a dopamine 0004 Citalopram, an SSRI antidepressant that is selec agonist and antagonist. Buspirone is commercially available tive for the 5HT1 receptor, is available commercially in immediate release tablet or Solution form under the trade under the trademark BUSPARTM in rapid release tablet form. marks CELEXATM and LEXAPROTM (s-citalopram enanti 0011 Buspirone (BUS) has been evaluated for its effect omer). Citalopram has been used, with intermittent Success, on motor disorders associated with Parkinson's disease or in combination with other drugs for treating depression in levodopa therapy; however, results have been mixed and patients with Parkinson's disease. Heinonen et al. (Drug contradictory. Bonifati et al. (Clin. Neuropharmacol., (1994 Safety, (July 1998), 19(1), 11-22) disclose the combined February), 17(1), 73-82) report mixed results in the treat administration of citalopram with Selegiline (deprenyl). ment of levodopa induced dyskinesia by administration of They disclose the administration of Selective Serotonin buspirone. Ross (Med. Hypotheses, (1987 March), 22(3), reuptake inhibitors (SSRIs), such as citalopram, to Parkin 321-8) suggests that the treatment of movement disorders Son's patients undergoing treatment with Selegiline. Rihmer with buspirone should be further evaluated. Hammerstad et et al. (International J. Psychiatry in Clin. Prac., (June al. (Clin. Neuropharmacol., (1986), 9(6), 556-560) report 2000), 4(2), 123-125) disclose the results of a study evalu that buspirone is ineffective in the treatment of Parkinson's ating the combined administration of Selegiline and citalo disease. Ludwig et al. (Clin. Neuropharmacol., (1986), 9(4), pram for the treatment of depression in patients with Par 373-8) report that at normal therapeutic (anti-anxiolytic) kinson's disease. Linasazoro (Parkinsonism & Related levels, buSpirone was no different than placebo in terms of Disorders, (April 2000), 6(2), 111-113) disclose the results its effect on dyskinesia. The combined use of an NMDA-RA of a case history wherein addition of citalopram to the and an anxiolytic agent, Such as buspirone, for the treatment anti-Parkinson's drug regime of a single patient actually of motor disorderS has not been disclosed. worsened her motor Symptoms. 0012 Trazodone (TRZ) is indicated for the treatment of 0005 Dell'Agnello et al. (Clin. Neuropharmacol., (July depression and is a classified as a triazolopyridine anxi August 2001), 24(4), 221-227) disclose the results of a study olytic/anti-depressant, psychotropic agent or a Serotonin evaluating the effect of SSRIs on the extrapyramidal symp antagonist reuptake inhibitor (SARI). TRZ is described in toms associated with Parkinson's disease. They report that U.S. Pat. No. 4,215,104 and No. 4,258,027. It is available SSRI's do not significantly worsen extrapyramidal Symp commercially in immediate release form under the trade tomatology and may ameliorate depression in patients with marks DESYRELTM, BENEFICATTM, BIMARANTM, Parkinson's disease. Other reports Suggest that the use of DEPRAXTM, DESIRELTM, MANEGANTM, MOLI US 2006/OO6381.0 A1 Mar. 23, 2006 PAXINTM, PRAGMARELTM, SIDERILTM, TAXAGONTM, Parkinson's disease. The Husbands et al. patent discloses THOMBRANTM, TRAZALONTM, TRAZOLANTM, TRA that “It should also be understood that the present invention ZONILTM and TRITTICOTM. The combined use of traZ is intended to include all methods of, and reasons for, odone with Selegiline in the treatment of depression asso inducing cognition enhancement in a mammal by adminis ciated with Parkinson's disease has been Suggested.
Load more

Recommended publications
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Video Course Evaluation Form My Name Is
    Garden State CLE 2000 Hamilton Avenue Hamilton, New Jersey 08619 (609) 584-1924 – Phone (609) 584-1920 - Fax Video Course Evaluation Form My Name is: __________________________________________ Name of Course: ______________________________________ My Street address: _____________________________________ City: _____________________ State: _____ Zip Code: ____ Email Address: ________________________________________ Please Circle the Appropriate Answer Instructors: Poor Satisfactory Good Excellent Materials: Poor Satisfactory Good Excellent CLE Rating: Poor Satisfactory Good Excellent Required: Secret words that appeared on the screen during the seminar. 1) __________________________ 2) _______________________ 3) __________________________ 4) _______________________ What did you like most about the seminar? _____________________________________________________________ _____________________________________________________________ What criticisms, if any, do you have? _____________________________________________________________ _____________________________________________________________ I certify that I watched, in its entirety, the above-listed CLE Course. Signature ___________________________________ Date_________ In order to receive your CLE credits, please send our payment and this completed form to Garden State CLE, 2000 Hamilton Avenue, Hamilton, New Jersey, 08619. BURLINGTON COUNTY BAR ASSOCIATION --- Interpreting Your Client’s Drug Lab Results: Were They Impaired? © Chris Baxter 2020 DO LAB RESULTS MATTER IN A DUI-D? YES ➢State
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Emulated Clinical Trials from Longitudinal Real-World
    Supplemental Material for “Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease” Table S1. ICD codes for PD cohort definition Type System Code Name icd9 3320 Paralysis agitans Inclusion icd10 G20 Parkinson's disease icd9 3316 Corticobasal degeneration icd9 3321 Secondary parkinsonism icd9 3330 Other degenerative diseases of the basal ganglia Exclusion icd10 G21 Secondary parkinsonism Progressive supranuclear ophthalmoplegia [Steele- icd10 G231 Richardson-Olszewski] icd10 G3185 Corticobasal degeneration Table S2. PD-indicated drugs and their corresponding ATC class names. The list below has been compiled by a domain expert based on the following sources: National Drug File – Reference Terminology (NDF-RT), Anatomical Therapeutic Chemical Classification System (ATC), and DrugBank (45). Drug ATC class code(s) ATC class name(s) Amantadine N04BB Adamantane derivatives Drugs used in erectile dysfunction; dopamine Apomorphine G04BE; N04BC agonists Belladonna alkaloids, tertiary amines; Atropine A03BA; S01FA anticholinergics Benztropine N04AC Ethers of tropine or tropine derivatives Biperiden N04AA Tertiary amines Bornaprine N04AA Tertiary amines Bromocriptine G02CB; N04BC Prolactine inhibitors; dopamine agonists Budipine N04BX Other dopaminergic agents Cabergoline G02CB; N04BC Prolactine inhibitors; dopamine agonists Carbidopa N/A N/A Dexetimide N04AA Tertiary amines Dihydroergocryptine N04BC Dopamine agonists Entacapone N04BX Other
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Management of Parkinson's Disease: an Evidence-Based Review
    Movement Disorders Vol. 17, Suppl. 4, 2002, p. i 2002 Movement Disorder Society Published by Wiley-Liss, Inc. DOI 10.1002/mds.5554 Editorial Management of Parkinson’s Disease: An Evidence-Based Review* Although Parkinson’s disease is still incurable, a large number tomatic control of Parkinson’s disease; prevention of motor com- of different treatments have become available to improve quality plications; control of motor complications; and control of non- of life and physical and psychological morbidity. Numerous jour- motor features. Based on a systematic review of the data, efficacy nal supplements have appeared in recent years highlighting one conclusions are provided. On the basis of a narrative non-system- or more of these and disparate treatment algorithms have prolifer- atic approach, statements on safety of the interventions are given ated. Although these are often quite useful, this “mentor analy- and finally, a qualitative approach is used to summarize the impli- sis” approach lacks the scientific rigor required by modern evi- cations for clinical practice and future research. dence-based medicine standards. The Movement Disorder Soci- This mammoth task has taken two years to complete and the ety, with generous but unrestricted support from representatives task force members, principal authors and contributors are to be of industry, have, therefore, commissioned a systematic review congratulated for their outstanding work. Physicians, the of the literature dealing with the efficacy and safety of available Parkinson’s disease research community and most of all patients treatments. The accompanying treatise is the result of a scrupu- themselves should welcome and embrace the salient findings of lous evaluation of the literature aimed at identifying those treat- this report as an effort to improve clinical practice.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Cytochrome P450 2D6.1 and Cytochrome P450 2D6.10 Differ in Catalytic Activity for Multiple Substrates
    Pharmacogenetics 2001, 11:477±487 Original article Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates Yamini Ramamoorthyb, Rachel F. Tyndaleab and Edward M. Sellersa±e aCentre for Addiction and Mental Health, Departments of bPharmacology, cMedicine and dPsychiatry, University of Toronto, Toronto, Canada and eSunnybrook and Women's College Health Science Centre, Toronto, Canada Received 24 October 2000; accepted 28 December 2000 CYP2D6 is involved in the metabolism of several classes of drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors and various amphetamines. 34 486 CYP2D6Ã10 is an allelic variant, producing an enzyme with Pro Ser and Ser Thr amino acid substitutions. Approximately 75% of Asians possess the Ã10 allele. We sought to further characterize CYP2D6.10 catalytically in vitro in a baculovirus expression system using various substrates and inhibitors, in comparison to CYP2D6.1 (wild-type). Using dextro- methorphan (DEX), P-methoxyamphetamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and (6)3,4-methylenedioxymethamphetamine (MDMA), the ratios of intrinsic clearance (Vmax/Km)ofÃ1toÃ10 were 50, 34, 22 and 123, respectively. The CYP2D6 substrates amitriptyline, and ( ) and (2) methamphetamine (MAMP) are both p-hydroxylated and N- demethylated (NDM). The intrinsic clearance Ã1/Ã10 ratios were 42, 30 and 67 for the p- hydroxylation; and 60, 120 and 157 for the NDM, respectively, illustrating chemical pathway and enantiomeric selectivity for MAMP. It was apparent that ( ) and (2) MAMP NDM and MDMA demethylenation were most signi®cantly different in CYP2D6.10. Using DEX as the substrate, the ratios of Ki(Ã10)/Ki(Ã1) for inhibitors were: budipine (1.3), sparteine (1.6), debrisoquine (8.1), ¯uoxetine (16), nor¯uoxetine (30), paroxetine (14), MDMA (21) and MMDA-2 (7.1), indicating that CYP2D6.10 shows drug-speci®c altered susceptibility to inhibition.
    [Show full text]
  • D.1 Information Needs of People with Parkinson's Disease and Their
    D.1 Information needs of people with Parkinson’s disease and their families and carers D.1.1 Impulse control behaviours Phu,A.L., Xu,Z., Brakoulias,V., Mahant,N., Fung,V.S., Moore,G.D., Martin,A., Starcevic,V., Krause,M., 20140821, Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients, Journal of Clinical Bibliographic reference Neuroscience, 21, 63-66, 2014 Full citation Phu,A.L., Xu,Z., Brakoulias,V., Mahant,N., Fung,V.S., Moore,G.D., Martin,A., Starcevic,V., Krause,M., 20140821, Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients, Journal of Clinical Neuroscience, 21, 63-66, 2014 Country/ies where the study Australia was carried out Study type Cohort study Aim of the study To examine the effect of impulse control disorder on quality of life in Parkinson’s disease patients. Study dates Study carried out between Jan 2009 and March 2011. received Oct 2012 accepted Feb 2013 published 2014 Source of funding Parkinson's Australia and the Nepean Research fund Sample size N = 100 Inclusion criteria Idiopathic PD according to Queen square brain bank criteria Exclusion criteria Those with active psychotic symptoms or severe cognitive impairment or other reasons which preclude an interview i.e. language barriers Details All patients interviewed by an experienced psychiatrist using expanded structured clinical interview from DSM-IV for obsessive compulsive disorder related spectrum disorders (OCSD) Corresponding diagnoses based on DSM IV criteria
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,441,047 B2 Desantis, Jr
    USOO64.41047B2 (12) United States Patent (10) Patent No.: US 6,441,047 B2 DeSantis, Jr. (45) Date of Patent: *Aug. 27, 2002 (54) COMBINATION THERAPY FOR TREATING OTHER PUBLICATIONS GLAUCOMA “Mechanisms of excitotoxicity in neurologic diseases, M. Flint Beal, The FASEB Journal, vol. 6, pp. 3338-3344, Dec., (75) Inventor: Louis DeSantis, Jr., Fort Worth, TX 1992. (US) “Excitotoxic Cell Death', Dennis W. Choi, Journal of Neu Assignee: Alcon Manufacturing Ltd., Ft. Worth robiology, vol. 23, No. 9, pp. 1261–1276, (1992). (73) “Morphology of Quisqualate-Induced Neurotoxicity in the (JP) Chicken Retina”, Sattayasai et al., Investigative Ophthalmol (*) Notice: This patent issued on a continued pros ogy & Visual Science, vol. 28, pp. 106-117, Jan., 1987. ecution application filed under 37 CFR “A quantitative analysis of the effects of excitatory neuro 1.53(d), and is subject to the twenty year toxins on retinal ganglion cells in the chick”, Tung et al., patent term provisions of 35 U.S.C. Visual Neuroscience, vol. 4, pp. 217-223, (1990). 154(a)(2). “Histologic changes in the inner retina of albino rats fol lowing intravitreal injection of monosodium L-glutamate', Subject to any disclaimer, the term of this Sisk et al., Graefe’s Arch. Clin. Exp. Ophtahlmol., vol. 223, patent is extended or adjusted under 35 pp. 250-258, (1985). U.S.C. 154(b) by 0 days. “N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina', Siliprandi et al., Visual NeurOScience, Vol. 8, pp. (21) Appl. No.: 09/267,966 567–573, (1992). “Effects of monosodium glutamate on chick embryo retina (22) Filed: Mar 12, 1999 in culture”, Reif Lehrer et al., Investigative Ophthalmology Related U.S.
    [Show full text]